Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination […]
The NCPE recommends that tixagevimab/cilgavimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that pembrolizumab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that inhaled liposomal amikacin, in addition to guideline-based therapy, for the treatment of adult patients with NTM lung infections caused by MAC and who have failed at least six months of guideline-based therapy, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that daratumumab (Darzalex®) in combination with bortezomib, cyclophosphamide and dexamethasone not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that NIVO+IPI not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
Congratulations to Dr. Roisin Adams who was elected Chair of the EC HTA Coordination Group yesterday in Brussels: https://health.ec.europa.eu/latest-updates/flash-report-member-state-coordination-group-hta-htacg-28-november-2022-2022-11-28_en
The NCPE recommends that pembrolizumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that cenobamate (Ontozry®) be considered for reimbursement as a second- or subsequent-line adjunctive treatment of focal onset seizures in adult patients with epilepsy who have failed treatment with two or more previous anti-seizure medicines, including at least one adjunctive therapy*.
The NCPE recommends that pegvaliase (Palynziq®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.